Doing now what patients need next
Pioneering diagnostics and pharma to create a healthier future for everyone
:quality(90)/)
In the spotlight
Roche publishes its half year results for 2026
Roche reports +6% (CER) sales growth in the first six months of 2026. Commenting on the results, CEO Thomas Schinecker said: “Our strong momentum continued in the first half of the year, driven by a 6% sales increase at constant exchange rates and significant positive pipeline development.”
What's it worth to make progress in cancer count
The World Cancer Congress 2026 advances global cancer care through flexible models, early detection, and equity. Roche’s diagnostics and medicines offer a full perspective from detection to ongoing care.
Our two divisions are focusing jointly on three disease areas that will account for almost 50% of the global disease burden by 2035: cancer, cardiovascular-metabolic diseases and neurological diseases.
:quality(90)/)
Investor information
We are Roche
We combine life-changing diagnostics and medicines to take on the toughest healthcare challenges, those that place the greatest strain on patients, families, communities, and health systems.
Guided by the experiences of patients, we are determined to prevent, stop and cure diseases so people can live healthier, longer lives.
:quality(90)/)
Our mission in action
:quality(90)/)
:quality(90)/)
:quality(90)/)
Read our stories
:quality(90)/)
:quality(90)/)
:quality(90)/)
Shape the future of healthcare
Join our global team of innovators, scientists, and changemakers
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)